Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation
© 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
BACKGROUND: Myelofibrosis (MF) is a clonal Philadelphia chromosome negative myeloproliferative neoplasm (Ph-MPN). MF is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (ruxo) is the-first-in-class Jak1/2 inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. In various malignancies neutrophil-to-lymphocyte ratio (NLR) has been indicated as predictor of progression free survival (PFS) and overall survival (OS). NLR might reflect the balance between systemic inflammation and immunity and is emerging as a prognostic biomarker in several neoplasms, including the hematological ones.
METHODS: We analyzed a cohort of 140 MF patients treated with ruxo to validate baseline NLR (as a continuous variable and as a cut-off 2) as predictor of OS and of ruxo treatment discontinuation.
RESULTS: We found that both baseline NLR as a continuous variable [HR 0.8 (95% CI: 0.7-0.9) (p = .006)] and NLR (<2 vs. ≥2) [HR 3.4 (95% CI: 1.6-7.0) (p = .001)] were significantly associated with OS. Censoring for patients undergone allotransplant, baseline NLR <2 was predictive of an earlier ruxo any-other-cause discontinuation [HR 3.7 (95%CI 1.7-8.3) (p < .001)].
CONCLUSIONS: NLR before starting ruxo treatment may be used as a simple and early predictor of OS and earlier ruxo discontinuation in clinical practice.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:112 |
|---|---|
| Enthalten in: |
European journal of haematology - 112(2024), 6 vom: 24. Apr., Seite 938-943 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Laganà, Alessandro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
82S8X8XX8H |
|---|
| Anmerkungen: |
Date Completed 26.04.2024 Date Revised 26.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.14188 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368221938 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368221938 | ||
| 003 | DE-627 | ||
| 005 | 20240426233652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240209s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.14188 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1388.xml |
| 035 | |a (DE-627)NLM368221938 | ||
| 035 | |a (NLM)38332702 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Laganà, Alessandro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.04.2024 | ||
| 500 | |a Date Revised 26.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Myelofibrosis (MF) is a clonal Philadelphia chromosome negative myeloproliferative neoplasm (Ph-MPN). MF is featured by an inflammatory condition that can also drive the progression of disease. Ruxolitinib (ruxo) is the-first-in-class Jak1/2 inhibitor approved for treatment of MF, proved to reduce spleen volume and decrease symptom burden. In various malignancies neutrophil-to-lymphocyte ratio (NLR) has been indicated as predictor of progression free survival (PFS) and overall survival (OS). NLR might reflect the balance between systemic inflammation and immunity and is emerging as a prognostic biomarker in several neoplasms, including the hematological ones | ||
| 520 | |a METHODS: We analyzed a cohort of 140 MF patients treated with ruxo to validate baseline NLR (as a continuous variable and as a cut-off 2) as predictor of OS and of ruxo treatment discontinuation | ||
| 520 | |a RESULTS: We found that both baseline NLR as a continuous variable [HR 0.8 (95% CI: 0.7-0.9) (p = .006)] and NLR (<2 vs. ≥2) [HR 3.4 (95% CI: 1.6-7.0) (p = .001)] were significantly associated with OS. Censoring for patients undergone allotransplant, baseline NLR <2 was predictive of an earlier ruxo any-other-cause discontinuation [HR 3.7 (95%CI 1.7-8.3) (p < .001)] | ||
| 520 | |a CONCLUSIONS: NLR before starting ruxo treatment may be used as a simple and early predictor of OS and earlier ruxo discontinuation in clinical practice | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a DIPSS | |
| 650 | 4 | |a IPSS | |
| 650 | 4 | |a Ruxolitinib (ruxo) | |
| 650 | 4 | |a myelofibrosis | |
| 650 | 4 | |a neutrophil‐to‐lymphocyte ratio (NLR) | |
| 650 | 4 | |a overall survival (OS) | |
| 650 | 7 | |a Nitriles |2 NLM | |
| 650 | 7 | |a ruxolitinib |2 NLM | |
| 650 | 7 | |a 82S8X8XX8H |2 NLM | |
| 650 | 7 | |a Pyrazoles |2 NLM | |
| 650 | 7 | |a Pyrimidines |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Passucci, Mauro |e verfasserin |4 aut | |
| 700 | 1 | |a Pepe, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Scalzulli, Emilia |e verfasserin |4 aut | |
| 700 | 1 | |a Carmosino, Ida |e verfasserin |4 aut | |
| 700 | 1 | |a Costa, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Bisegna, Maria Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Ielo, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Martelli, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Breccia, Massimo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 112(2024), 6 vom: 24. Apr., Seite 938-943 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:112 |g year:2024 |g number:6 |g day:24 |g month:04 |g pages:938-943 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.14188 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 112 |j 2024 |e 6 |b 24 |c 04 |h 938-943 | ||